cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Gh Research Plc
2 own
1 watching
Current Price
$12.93
$-1.41
(-9.83%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
579.59M
52-Week High
52-Week High
14.64000
52-Week Low
52-Week Low
5.05000
Average Volume
Average Volume
0.05M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization579.59M
icon52-Week High14.64000
icon52-Week Low5.05000
iconAverage Volume0.05M
iconDividend Yield--
iconP/E Ratio--
What does the Gh Research Plc do?
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trial and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate, and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
Read More
News & Events about Gh Research Plc.
Ticker Report
11 months ago
Shares of GH Research PLC (NASDAQ:GHRS Get Rating) gapped down prior to trading on Thursday . The stock had previously closed at $12.42, but opened at $11.77. GH Research shares last traded at $12.38, with a volume of 14,555 shares trading hands. Wall Street Analysts Forecast Growth Several ...
Globe Newswire
1 year ago
DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2022 and gave ...
Globe Newswire
1 year ago
Initial approvals received for Phase 2b trial of GH001 in TRD (GH001-TRD-201), initiation of this trial expected in Q1 2023Development of proprietary aerosol delivery device for GH001 progressed, IND submission with this device expected in Q3 2023Phase 1 trial of GH002 in healthy volunteers (GH002-...
Ticker Report
1 year ago
Exchange Traded Concepts LLC lifted its holdings in shares of GH Research PLC (NASDAQ:GHRS Get Rating) by 373.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,885 shares of the companys stock after acquiring an ...
Frequently Asked Questions
Frequently Asked Questions
What is Gh Research Plc share price today?
plus_minus_icon
Can Indians buy Gh Research Plc shares?
plus_minus_icon
How can I buy Gh Research Plc shares from India?
plus_minus_icon
Can Fractional shares of Gh Research Plc be purchased?
plus_minus_icon
What are the documents required to start investing in Gh Research Plc stocks?
plus_minus_icon
What is today’s traded volume of Gh Research Plc?
plus_minus_icon
What is today’s market capitalisation of Gh Research Plc?
plus_minus_icon
What is the 52-Week High and Low Range of Gh Research Plc?
plus_minus_icon
What percentage is Gh Research Plc down from its 52-Week High?
plus_minus_icon
What percentage is Gh Research Plc up from its 52-Week Low?
plus_minus_icon
Current Price
$12.93
$-1.41
(-9.83%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00